• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 13, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

NIA awards $4.23 million to establish Cleveland Alzheimer’s Disease Research Center

Bioengineer by Bioengineer
July 9, 2019
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

New center to be one of 31 National Institute on Aging funded centers in the nation

IMAGE

Credit: Cleveland Alzheimer’s Disease Research Center

July 9, 2019, CLEVELAND: The National Institute on Aging of the National Institutes of Health (NIH) awarded a $4.23 million grant to establish the Cleveland Alzheimer’s Disease Research Center. The two-year award will support the development of a multi-institution collaborative focused on accelerating research for Alzheimer’s disease and related dementias.

The Cleveland Alzheimer’s Disease Research Center, led by James Leverenz, M.D., of Cleveland Clinic, will be one of 31 NIH-funded Alzheimer’s Disease Research Centers of Excellence in the country that are part of the Alzheimer’s Disease Research Centers Program. The new multi-institutional center – the first in Ohio – brings together top researchers and clinicians from Case Western Reserve University, Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, the MetroHealth System and University Hospitals.

The Alzheimer’s Disease Research Centers Program is a national network of researchers and clinicians at major medical institutions across the United States. Researchers at these centers are working to translate research advances into improved diagnosis and care for people with Alzheimer’s disease, as well as finding a way to cure and possibly prevent the disease.

More than 5.3 million Americans suffer from Alzheimer’s disease. That number is expected to nearly triple by 2050.

“The Cleveland Alzheimer’s Disease Research Center will bring together the considerable expertise from the Northeast Ohio medical and academic communities to focus on one of the largest health care crises facing our country and the state of Ohio,” said Dr. Leverenz, director of Cleveland Clinic’s Lou Ruvo Center for Brain Health in Cleveland. “The center will create a robust infrastructure to expedite research to better understand and treat Alzheimer’s disease and related dementias. As a multi-institution collaboration with a large patient population and deep expertise in dementia research and treatment, we are uniquely positioned to be a high-impact center.”

“This is an exciting development for Cleveland and doctors working together from many hospitals can do great things,” said Alan Lerner, M.D., director of the Brain Health and Memory Center at University Hospitals Cleveland Medical Center. “Our aim is to advance research and ultimately improve the lives of those affected by this devastating disease.”

The new center will support a wide range of studies while also educating scientists, health care professionals and the public on the causes and treatment of dementias. It will have eight cores led by experts across the participating institutions: Administrative (Dr. Leverenz), Biomarkers (Lynn Bekris, Ph.D., Cleveland Clinic); Clinical (Dr. Lerner, UH/CWRU); Data Management and Statistics (Jonathan Haines, Ph.D., CWRU); Neuropathology (Mark Cohen, M.D., and Brian Appleby, M.D., CWRU/UH); Outreach, Recruitment and Engagement (Martha Sajatovic, M.D., UH/CWRU), Research Education (Xiongwei Zhu, Ph.D., CWRU) and Translational Therapeutics (Andrew Pieper, M.D., Ph.D., Harrington Discovery Institute at UH/VA).

“Our team is eager to contribute to the new center, providing statistical and computational expertise leveraging our extensive experience leading large-scale studies that integrate ‘omics’ and clinical data across tens of thousands of lives,” said Dr. Haines, chair of Case Western Reserve’s Department of Population and Quantitative Health Sciences. “Alzheimer’s cuts across all ethnicities and all socioeconomic classes and is a huge burden in NE Ohio. Our diverse urban and rural population, combined with detailed genetic and clinical information, and the wealth of additional data from electronic medical records, means this new Cleveland center is uniquely positioned to contribute significantly to the national research agenda.”

Particular areas of focus for the center will be atypical Alzheimer’s disease (e.g. “rapidly progressive”), Lewy body dementia, healthy individuals at risk for developing dementia, and underserved populations. In addition to community outreach, the center will develop infrastructure and support for promising new investigators and promote the translation of findings from the laboratory to new therapeutics for these devastating diseases.

To learn more about the Cleveland Alzheimer’s Disease Research Center, please contact [email protected] or 1-833-311- ADRC (2372).

The Cleveland Alzheimer’s Disease Research Center is funded by NIH grant P30AG062428.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

###

Media Contact
Alicia Reale
[email protected]

Original Source

https://newsroom.clevelandclinic.org/2019/07/09/national-institute-on-aging-awards-4-23-million-to-establish-cleveland-alzheimers-disease-research-center/

Tags: AgingAlzheimerClinical TrialsGeneticsMedicine/Healthneurobiology
Share12Tweet8Share2ShareShareShare2

Related Posts

Mizzou Researchers Uncover New Insights into Immune Response to Influenza

Mizzou Researchers Uncover New Insights into Immune Response to Influenza

August 13, 2025
‘Essentiality’ Scan Uncovers Microbe’s Vital Survival Toolkit

‘Essentiality’ Scan Uncovers Microbe’s Vital Survival Toolkit

August 13, 2025

First Gyrodactylus perccotti Found on Chinese Sleeper

August 13, 2025

Reducing Oxidative Stress in Early Malaria with Capsicum

August 13, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    140 shares
    Share 56 Tweet 35
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    79 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    58 shares
    Share 23 Tweet 15
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

WashU Secures Up to $5.2 Million in Federal Funding to Enhance Biomanufacturing Capabilities

NRG Oncology Announces New Leadership for NCORP and Veterans Affairs Research Programs

Cerium’s Unique Redox Properties in BaFe1−xCexO3−δ Perovskites

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.